Theaflavin-3,3'-digallate

Intervention

2 papers3 findings

PubChem

  • 2 independent labs in 1 country
  • Funders: Changzhou Science and Technology Bureau and 4 more
  • Animals2

Outcomes

3

Osteoarthritis

downin mice1

1 study
  1. Theaflavin-3,3'-digallate protects against osteoarthritis in mice.

    “Animal experiments further confirmed that TF3 exerted anti-senescence effects and delayed joint degeneration.”

    Animalsin mouse model of destabilization of the medial meniscus (DMM)joint

    Theaflavin-3,3'-digallate attenuates chondrocyte senescence via modulating FGF7 and KEAP1/NRF2 signaling pathway

    Free radical biology & medicine19 May 2026

More on Osteoarthritis

Cellular senescence

downin mouse cells1

1 study
  1. Theaflavin-3,3'-digallate inhibits cellular senescence in mouse cells.

    “TF3 suppressed the expression of senescence-associated proteins, including p16Ink4a, p21, IL-6, and MMP13”

    Cellsin IL-1β induced cell senescence modelcartilage

    Theaflavin-3,3'-digallate attenuates chondrocyte senescence via modulating FGF7 and KEAP1/NRF2 signaling pathway

    Free radical biology & medicine19 May 2026

More on Cellular senescence

Non-alcoholic fatty liver disease

downin mice1

1 study
  1. Theaflavin-3,3'-digallate decreases non-alcoholic fatty liver disease in mice.

    “A macrophage membrane-coated nanoparticle (MM@NP-TFDG) delivered TFDG specifically to hepatic macrophages, suppressed the Mas-PKM2-Spi1 lactylation axis, and ameliorated MASLD pathology in vivo.”

    Animalsin diet-induced MASLD micemacrophage membrane-coated nanoparticle (MM@NP-TFDG)liver

    Myeloid Mas drives pyruvate kinase M2-mediated Spi1 lactylation to fuel inflammatory senescence in MASLD

    Signal transduction and targeted therapy19 May 2026

More on Non-alcoholic fatty liver disease

Latest

Nov 2025: 0Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 2Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 02 in 12 months